Conversation with The Cancer LetterFree PH.AI CEO Hyde: With Big Data, pharma will focus on the measurement of value March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Roche CEO O’Day: Our investment in Flatiron will accelerate their mission March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
Free Roche to acquire Flatiron Health for $2.1 billion,with focus on real-world data March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
FreeTrials & Tribulations Diversity within Diversity: Lessons from the Latinos of South Texas February 23, 2018Vol.44 No.08By Amelie G. Ramirez and Ruben A. Mesa
Conversation with The Cancer LetterFree UT Health San Antonio’s link with MD Anderson goes live; How does it work? February 23, 2018Vol.44 No.08By Paul Goldberg
Conversation with The Cancer LetterFree His six-month “listening tour” almost over, Sharpless discusses his vision for NCI February 23, 2018Vol.44 No.08By Paul Goldberg
FreeTrials & Tribulations A Cancer Patient’s War on Cancer February 16, 2018Vol.44 No.07By C. Anthony "Tony" Blau
NCI Sharpless: NCI should increase funding for RPG pool to maintain success rates for R01s February 16, 2018Vol.44 No.07
A confusing Valentine:White House proposes cutting NIH by 27 percent, and—at the same time—reverses the cut February 16, 2018Vol.44 No.07By Paul Goldberg
Dissenters in anti-tobacco movement cite National Academy report in claim that “e-cigarettes are saving lives.” Nope, the NAS report’s authors sayNope, the NAS report’s author say February 09, 2018Vol.44 No.06By Matthew Bin Han Ong
